title: Polycystic ovary syndrome update in adolescence.
abstract: OBJECTIVE
  To provide an overview of our current understanding of polycystic ovary syndrome, its epidemiology and natural history, and potential therapeutic options.
  
  
  RESULTS
  Polycystic ovary syndrome is estimated to affect 5-10% of premenopausal women. While once thought to affect primarily adult women, polycystic ovary syndrome is frequently diagnosed during adolescence and may be increasing in prevalence secondary to the recent trend of increasing obesity among teenagers. Adolescents and young women often present with hirsutism, irregular menses, and obesity. There is increasing evidence that these women are also at increased risk later in life for cardiovascular and metabolic disease. Early treatment may prevent disease progression. Treatment options have focused on improving clinical symptoms of androgen excess and anovulation. Newer therapies, such as insulin-sensitizing agents, are beneficial in correcting the underlying metabolic disorder and, therefore, theoretically may have a more significant impact on reducing associated long-term morbidity.
  
  
  CONCLUSIONS
  An increasing number of adolescents are presenting with signs of polycystic ovary syndrome. While once thought to primarily affect appearance and fertility, it has become clear that women with this syndrome may also potentially face long-term health sequelae. Efforts should be made to diagnose and treat these women in adolescence to minimize the development of symptoms, and prevent the onset of cardiovascular and metabolic problems.
authors.affiliation: Division of Adolescent, Young Adult Medicine, Children's Hospital Boston, Boston, MA 02115, USA. areej.hassan@childrens.harvard.edu
authors.forename: Areej
authors.initials: A
authors.lastname: Hassan
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Gordon
mesh_terms: D000293:Adolescent; D000465:Algorithms; D000726:Androgen Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity / Q000209:etiology; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy
chemical_list: D000726:Androgen Antagonists; D007004:Hypoglycemic Agents; D008687:Metformin